|
See related Januvia tab information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Zuellig |
|
Contents |
Sitagliptin phosphate |
|
Indications |
Monotherapy: Adjunct to diet & exercise to improve glycemic control in type 2 DM. Combination therapy: For type 2 DM to improve glycemic control in combination w/ metformin, sulfonylurea or metformin & PPARγ agonist (eg thiazolidinedione) or insulin or metformin & sulfonylurea when diet & exercise plus the single agent do not provide adequate glycemic control.
Click to view Januvia detailed prescribing infomation |
|
Dosage |
Monotherapy or in combination w/ metformin, sulfonylurea, insulin (w/ or w/o metformin), PPARγ agonist, metformin plus a sulfonylurea, or metformin plus PPARγ agonist 100 mg once daily. Moderate renal insufficiency 50 mg once daily.
Click to view Januvia detailed prescribing infomation |
|
Overdosage |
View Januvia overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
[Click for Januvia detailed prescribing infomation] |
|
Special Precautions |
Not for type 1 DM or treatment of diabetic ketoacidosis. Monitor for signs/symptoms of pancreatitis. Moderate or severe renal insufficiency or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis. Hypoglycemia in combination w/ a sulfonylurea or insulin. Childn <18 yr. Pregnancy & lactation.
Click to view Januvia detailed prescribing infomation |
|
Adverse Drug Reactions |
Abdominal pain, nausea, vomiting, diarrhea, hypersensitivity reactions. Combination therapy: Hypoglycemia, cough, headache, upper resp tract, fungal & skin infection, peripheral edema, flu.
View ADR Monitoring Form |
|
Side Effects |
View Januvia side effects |
|
Drug Interactions |
[Click for Januvia detailed prescribing infomation]
View more drug interactions with Januvia |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Storage |
View Januvia storage conditions for details to ensure optimal shelf-life. |
|
Mechanism of Action |
View Januvia mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
